Emerging technologies in autoantibody testing for rheumatic diseases.

Area of Science:

• Immunology
• Rheumatology
• Clinical Diagnostics

Background:

• Antinuclear antibodies (ANAs) are key biomarkers for diagnosing systemic lupus erythematosus (SLE) and other systemic autoimmune rheumatic diseases (SARD).
• The conventional indirect immunofluorescence (IIF) slide test, while standard, has limitations in specificity for SLE and may miss certain SARD-associated autoantibodies.
• Advancements in immunoassay technologies offer potential for enhanced diagnostic and prognostic information.

Purpose of the Study:

• To review the current landscape of antinuclear antibody (ANA) testing methodologies.
• To explore the utility of multiplex techniques for detecting a broader range of autoantibodies.
• To discuss the potential of point-of-care testing and early disease detection strategies.

Main Methods:

• Review of current literature on ANA testing and related immunoassay technologies.
• Analysis of multiplex assay performance characteristics compared to traditional methods.
• Discussion of emerging trends in autoimmune disease diagnostics.

Main Results:

• Indirect immunofluorescence (IIF) remains a standard but has limitations in specificity and comprehensive detection.
• Alternative immunoassays and multiplex techniques show promise for improved diagnostic accuracy and broader autoantibody profiling.
• Point-of-care testing and early detection approaches are under development.

Conclusions:

• While IIF is established, newer immunoassay platforms offer advantages in diagnosing SARD.
• Multiplex assays can provide a more comprehensive autoantibody profile, aiding in diagnosis and prognosis.
• Future directions include point-of-care testing and application in early-stage disease detection.